Stock Events

23andMe 

$0.4
154
-$0-1.15% Today

Statistics

Day High
-
Day Low
-
52W High
2.21
52W Low
0.39
Volume
2,039,390
Avg. Volume
4,742,030
Mkt Cap
125.23M
P/E Ratio
-0.36
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MayExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-0.19
-0.13
-0.06
-0
Expected EPS
-0.1118
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ME. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Analyst Ratings

0.47$Average Price Target
The highest estimate is $0.47.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Show more...
CEO
Employees
769
Country
US
ISIN
US90138Q1085

Listings